⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231035 | 0.93 | — | — | |
| SCHEMBL229043 | 0.93 | — | — | |
| SCHEMBL28939344 | 0.91 | — | — | |
| SCHEMBL3384131 | 0.90 | — | — | |
| SCHEMBL11773212 | 0.90 | — | — | |
| SCHEMBL25238188 | 0.90 | — | — | |
| SCHEMBL19297 | 0.90 | — | — | |
| SCHEMBL11777486 | 0.90 | — | — | |
| SCHEMBL7393104 | 0.90 | — | — | |
| SCHEMBL11773650 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146345-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| WO-2021226206-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | claimed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | claimed |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2012-11-01 | — | — | US | claimed |
| US-8043823-B2 | Methods of identifying agonists and antagonists of hTASR bitter taste receptors | DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG (DE) | 2011-10-25 | — | — | US | claimed |
| US-20100184796-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE (DE) | 2010-07-22 | — | — | US | claimed |
| US-20100130498-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSHES INSTITUT FUR ERNAHRUNGSFORSCHUNG POTSDAM- REHBRUCKE (DE) | 2010-05-27 | — | — | US | claimed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | claimed |
| EP-2132564-A2 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts (DE) | 2009-12-16 | — | — | EP | claimed |
| EP-2132563-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts (DE) | 2009-12-16 | — | — | EP | claimed |
| EP-1991215-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | Cenix Bioscience GmbH (DE) | 2008-11-19 | — | — | EP | claimed |
| WO-2008135232-A1 | USE AND COMPOSITIONS OF PURINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CORTESE RICCARDO (IT) | 2008-11-13 | — | — | WO | claimed |
| WO-2008119526-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2008-10-09 | — | — | WO | claimed |
| WO-2008119527-A2 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POSTDAM-REHBRÜCKE STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2008-10-09 | — | — | WO | claimed |
| EP-1975612-A1 | Agonists of bitter taste receptors and uses thereof | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand (DE) | 2008-10-01 | — | — | EP | claimed |
| EP-1975611-A1 | Agonists of bitter taste receptors and uses thereof | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand (DE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007115805-A2 | AURORA KINASE INHIBITORS | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2007-10-18 | — | — | WO | claimed |
| WO-2007101710-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2007-09-13 | — | — | WO | claimed |
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| EP-3512852-B1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024129963-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-3191484-B1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| US-20240182494-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240132521-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024059563-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024044570-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4313033-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313986-A1 | PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS | Genentech, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240034739-A1 | PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS | GENENTECH, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| US-20240025849-A1 | INHIBITORS OF NO PRODUCTION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2024-01-25 | — | — | US | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-3781571-B1 | N-[4-OXO-2,3-DIHYDRO-PYRIDO[3,2-B][1,4]OXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOLE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) | HOFFMANN LA ROCHE (CH) | 2024-01-17 | — | — | EP | disclosed |
| EP-4294447-A1 | POLYSACCHARIDE COMPLEX | Acaryon GmbH (DE) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023236778-A1 | TRIFUNCTIONAL COMPOUND AND USE THEREOF | 北京大学 | 2023-12-14 | — | — | WO | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023227601-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | disclosed |
| EP-3704097-B1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-4262878-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-20230303995-A1 | ISOLATION OF NUCLEIC ACIDS AT ELEVATED TEMPERATURES | BIOECHO LIFE SCIENCES GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| WO-2023166099-A1 | RNA LIPID NANOPARTICLES (LNPs) COMPRISING A POLYOXAZOLINE AND/OR POLYOXAZINE POLYMER | BioNTech SE (DE) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023165681-A1 | RNA LIPID NANOPARTICLES (LNPS) COMPRISING A POLYOXAZOLINE AND/OR POLYOXAZINE POLYMER | BioNTech SE (DE) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023161427-A1 | VIRAL COMBINATION THERAPY | EISBACH BIO GMBH (DE) | 2023-08-31 | — | — | WO | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4204087-A1 | INHIBITORS OF NO PRODUCTION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2023-07-05 | — | — | EP | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-11673892-B2 | Bicyclic compounds for use as RIP1 kinase inhibitors | GENENTECH, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3021847-B1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| WO-2023073222-A1 | INHIBITORS OF VIRAL HELICASES BINDING TO A NOVEL ALLOSTERIC BINDING SITE | EISBACH BIO GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-3802730-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-04-19 | — | — | EP | disclosed |
| US-20230112012-A1 | FAP INHIBITOR | UNIVERSITAT HEIDELBERG (DE) | 2023-04-13 | — | — | US | disclosed |
| US-11607396-B2 | Bicyclic amide compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4146345-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2023034530-A1 | METHODS OF IMPROVING GROWTH AND FUNCTION OF IMMUNE CELLS | TEON THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-4143191-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | disclosed |
| EP-4126053-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11572384-B2 | Unusual substrates of tubulin tyrosine ligase | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2023-02-07 | — | — | US | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3694858-B1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-01-11 | — | — | EP | disclosed |
| US-20230002391-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220402960-A1 | BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-12-22 | — | — | US | disclosed |
| EP-3908586-B1 | BICYCLIC PYRROLOTRIAZOLR KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022253311-A1 | HPK1 INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022204368-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022175390-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2022-08-25 | — | — | WO | disclosed |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-07-07 | — | — | US | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022133288-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
| EP-4001275-A1 | (S)-ENANTIOMER OF MEPAZINE AS PARACASPASE (MALT1) INHIBITOR FOR THE TREATMENT OF CANCER | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2022-05-25 | — | — | EP | disclosed |
| US-20220144822-A1 | PROCESS FOR THE PREPARATION OF A SUBSTITUTED IMIDAZOQUINOLINE | BioNTech SE (DE) | 2022-05-12 | — | — | US | disclosed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-RE48992-E1 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2022-03-29 | — | — | US | disclosed |
| WO-2022043465-A1 | INHIBITORS OF NO PRODUCTION | MAX DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-03-03 | — | — | WO | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| US-20220024944-A1 | COMPOUNDS TARGETING MUTANT CALRETICULIN | MYELOPRO DIAGNOSTICS AND RESEARCH GMBH (AT) | 2022-01-27 | — | — | US | disclosed |
| EP-3935047-A1 | PROCESS FOR THE PREPARATION OF A SUBSTITUTED IMIDAZOQUINOLINE | BioNTech SE (DE) | 2022-01-12 | — | — | EP | disclosed |
| EP-3061779-B2 | Coating agent and the use of same, in particular for forming a protective coating on a surface | MIPA SE (DE) | 2022-01-05 | — | — | EP | disclosed |
| EP-3013818-B1 | (S)-ENANTIOMER OF MEPAZINE AS PARACASPASE (MALT1) INHIBITOR FOR TREATING CANCER | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2021-12-29 | — | — | EP | disclosed |
| US-20210387982-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-12-16 | — | — | US | disclosed |
| EP-3526219-B1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20210379067-A1 | DASATINIB AND ANOTHER 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-12-09 | — | — | US | disclosed |
| US-11185548-B2 | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases | HELMHOLTZ ZENTRUM MUNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-11-30 | — | — | US | disclosed |
| US-20210363172-A1 | 5'-CAP-TRINUCLEOTIDE- OR HIGHER OLIGONUCLEOTIDE COMPOUNDS AND THEIR USE IN STABILIZING RNA, EXPRESSING PROTEINS IN THERAPY | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| WO-2021234181-A1 | USE OF FAP INHIBITOR IN A METHOD OF DIAGNOSIS | Universität Heidelberg (DE) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021229066-A1 | ISOLATION OF NUCLEIC ACIDS AT ELEVATED TEMPERATURES | BIOECHO LIFE SCIENCES GMBH (DE) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021226206-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
| US-20210340170-A1 | 5'-CAP COMPOUNDS AND THEIR USES IN STABILIZING RNA, EXPRESSING PROTEINS AND IN THERAPY | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
| US-20210340151-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901151-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3464260-B1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UNIV MUENCHEN TECH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| WO-2021195198-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210290629-A1 | ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES | FORSCHUNGSZENTRUM BORSTEL LEIBNIZ-ZENTRUM FUER MEDIZIN UND BIOWISSENSCHAFTEN (DE) | 2021-09-23 | — | — | US | disclosed |
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072617-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3280705-B1 | PYRONE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2021-07-21 | — | — | EP | disclosed |
| EP-3846854-A2 | IMPROVED POLYPEPTIDE COUPLED ANTIBIOTICS | Mier, Walter (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-20210179602-A1 | A 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-11001591-B2 | TRAF 6 inhibitors | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-05-11 | — | — | US | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3802730-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2021-04-14 | — | — | EP | disclosed |
| US-10975095-B2 | — | — | 2021-04-13 | — | — | US | disclosed |
| EP-3796975-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10933036-B2 | — | — | 2021-03-02 | — | — | US | disclosed |
| EP-3781571-A1 | N-[4-OXO-2,3-DIHYDRO-1,5-BENZOXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL E-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) | F. Hoffmann-La Roche AG (CH) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781206-A2 | A 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-20210038749-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2021-02-11 | — | — | US | disclosed |
| US-20210032271-A1 | PYRIDINE LACTAM COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| EP-3768678-A1 | TRAF 6 INHIBITORS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2021-01-27 | — | — | EP | disclosed |
| US-20210017183-A1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-01-21 | — | — | US | disclosed |
| EP-3765477-A1 | 5'-CAP-TRINUCLEOTIDE- OR HIGHER OLIGONUCLEOTIDE COMPOUNDS AND THEIR USES IN STABILIZING RNA, EXPRESSING PROTEINS AND IN THERAPY | BioNTech RNA Pharmaceuticals GmbH (DE) | 2021-01-20 | — | — | EP | disclosed |
| US-10894918-B2 | Liquid crystal medium containing polymerisable compounds | MERCK PATENT GMBH (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2021-01-14 | — | — | US | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3749733-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2020-12-16 | — | — | EP | disclosed |
| EP-3749663-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2020-12-16 | — | — | EP | disclosed |
| EP-3529333-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| WO-2020225285-A1 | PDEDELTA INHIBITORS | UNIVERSITÉ DU LUXEMBOURG (LU) | 2020-11-12 | — | — | WO | disclosed |
| US-20200283446-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3704097-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2020-09-09 | — | — | EP | disclosed |
| US-20200277297-A1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-09-03 | — | — | US | disclosed |
| US-10759996-B2 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2020-09-01 | — | — | US | disclosed |
| EP-3694858-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200179511-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-11 | — | — | US | disclosed |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-10669278-B2 | TRAF 6 inhibitors | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-06-02 | — | — | US | disclosed |
| EP-3652178-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2020-05-20 | — | — | EP | disclosed |
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
| EP-3643713-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | iOmx Therapeutics AG (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-2852572-B1 | CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20200085833-A1 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN TREATING DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2020-03-19 | — | — | US | disclosed |
| US-10590344-B2 | Liquid crystal medium containing polymerisable compounds | MERCK PATENT GMBH (DE) | 2020-03-17 | — | — | US | disclosed |
| EP-3615068-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615055-A1 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-10570335-B2 | Liquid crystal medium containing polymerisable compounds | MERCK PATETN GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| US-10568852-B2 | Combination compositions and their use in methods for treating obesity and obesity-related disorders | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-02-25 | — | — | US | disclosed |
| US-20200055948-A1 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2020-02-20 | — | — | US | disclosed |
| WO-2019233913-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2019-12-12 | — | — | WO | disclosed |
| EP-3558304-A2 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN TREATING DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3560516-A1 | COMBINATION THERAPY INCLUDING BETA-SITOSTEROL IN COMBINATION WITH AT LEAST ONE OF A BRAF INHIBITOR, A MEK INHIBITOR OR AN ERK INHIBITOR AND METHODS AND USE THEREOF | Bergen Teknologioverforing AS (NO) | 2019-10-30 | — | — | EP | disclosed |
| WO-2019202160-A2 | A 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019204537-A1 | N-[4-OXO-2,3-DIHYDRO-1,5-BENZOXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL E-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) | GENENTECH, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190307760-A1 | ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES | FORSCHUNGZENTRUM BORSTEL LEIBNIZ-ZENTRUM FÜR MEDIZIN UND BIOWISSENSCHAFTEN (DE) | 2019-10-10 | — | — | US | disclosed |
| EP-3548484-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019180207-A1 | TRAF 6 INHIBITORS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019175356-A1 | 5'-CAP-TRINUCLEOTIDE- OR HIGHER OLIGONUCLEOTIDE COMPOUNDS AND THEIR USES IN STABILIZING RNA, EXPRESSING PROTEINS AND IN THERAPY | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2019-09-19 | — | — | WO | disclosed |
| US-10407398-B2 | Inhibitors of Pseudomonas aeruginosa LecB | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-09-10 | — | — | US | disclosed |
| US-20190264105-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2019-08-29 | — | — | US | disclosed |
| EP-3529333-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2019-08-28 | — | — | EP | disclosed |
| EP-3529332-A2 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2019-08-28 | — | — | EP | disclosed |
| EP-3526219-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2019-08-21 | — | — | EP | disclosed |
| WO-2019154740-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154886-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154859-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2019-08-15 | — | — | WO | disclosed |
| US-20190241808-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| EP-3368637-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3512852-A1 | TRAF 6 INHIBITORS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20190211025-A1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2019-07-11 | — | — | US | disclosed |
| US-20190144493-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-05-16 | — | — | US | disclosed |
| EP-3481392-A1 | ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-10280179-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2019-05-07 | — | — | US | disclosed |
| US-20190127382-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3095827-B1 | COMPOSITIONS BASED ON ORGANOSILICON COMPOUNDS AND THEIR USE AS COATING MATERIAL, IN PARTICULAR FOR THE CORROSION PROTECTION OF METALS | MIPA SE (DE) | 2019-04-24 | — | — | EP | disclosed |
| WO-2019072942-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| EP-3464260-A2 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2019-04-10 | — | — | EP | disclosed |
| EP-3061779-B1 | Coating agent and the use of same, in particular for forming a protective coating on a surface | MIPA SE (DE) | 2019-04-10 | — | — | EP | disclosed |
| US-10253236-B2 | Environmental friendly well treatment fluids comprising an ester | AMRIL AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |
| EP-3419987-A1 | AFFINITY LIGAND FOR THE PURIFICATION OF GLYCOSYLATED BIOMOLECULES | Hochschule für Technik und Wirtschaft (HTW) Berlin (DE) | 2019-01-02 | — | — | EP | disclosed |
| US-20180371319-A1 | LIQUID CRYSTAL MEDIUM CONTAINING POLYMERISABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-12-27 | — | — | US | disclosed |
| US-20180362475-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-12-20 | — | — | US | disclosed |
| EP-3024910-B1 | ENVIRONMENTAL FRIENDLY WELL TREATMENT FLUIDS COMPRISING AN ESTER | AMRIL AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-10138242-B2 | Pyrazolopyridine derivatives and their use in therapy | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| US-20180312756-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2018-11-01 | — | — | US | disclosed |
| WO-2018201051-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018201056-A1 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | disclosed |
| EP-2861675-B1 | DISPERSING AGENT COMPRISING FILLERS OR PIGMENTS | AMRIL AG (CH) | 2018-09-05 | — | — | EP | disclosed |
| EP-3368637-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2018-09-05 | — | — | EP | disclosed |
| EP-2137530-B1 | ANTAGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INST FUER ERNAEHRUNGSFORSCHUNG POTSDAM REHBRUECKE STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-20180186789-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180187080-A1 | LIQUID CRYSTAL MEDIUM CONTAINING POLYMERISABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| WO-2018115319-A2 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN TREATING DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179446-A1 | LIQUID CRYSTAL MEDIUM CONTAINING POLYMERISABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| WO-2018100070-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-07 | — | — | WO | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155310-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA LECB | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2018-06-07 | — | — | US | disclosed |
| US-20180147163-A1 | COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3317269-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018073158-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018073159-A2 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018073193-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018065607-A1 | CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN RELATED PEPTIDASE 6 (KLK6) | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2018-04-12 | — | — | WO | disclosed |
| EP-3305781-A1 | CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN-RELATED PEPTIDASE 6 (KLK6) | Deutsches Krebsforschungszentrum (DE) | 2018-04-11 | — | — | EP | disclosed |
| EP-3297676-A2 | COMBINATION OF TRPM8-AGONIST AND NACHR-AGONIST FOR TREATMENT OF OBESITY AND RELATED DISORDERS AND FOR WEIGHT REDUCTION | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2018-03-28 | — | — | EP | disclosed |
| WO-2018050286-A1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20180065982-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-03-08 | — | — | US | disclosed |
| EP-3280705-A1 | PYRONE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2018-02-14 | — | — | EP | disclosed |
| EP-3274341-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA LECB | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2018-01-31 | — | — | EP | disclosed |
| WO-2018007430-A1 | ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES | FORSCHUNGSZENTRUM BORSTEL LEIBNIZ-ZENTRUM FÜR MEDIZIN UND BIOWISSENSCHAFTEN (DE) | 2018-01-11 | — | — | WO | disclosed |
| EP-3266454-A1 | ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften (DE) | 2018-01-10 | — | — | EP | disclosed |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9840504-B2 | Pyrazolopyridine derivatives and their use in therapy | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGZENTRUM FUER GESUNDHEIT UN (DE) | 2017-12-12 | — | — | US | disclosed |
| WO-2017207556-A2 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017194734-A1 | MEANS AND METHODS FOR TREATING MYCOBACTERIAL DISEASES | Technische Universität München (DE) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017186855-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2017-11-02 | — | — | WO | disclosed |
| US-9802956-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MUNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-3233880-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| EP-3217982-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2017-09-20 | — | — | EP | disclosed |
| WO-2017144099-A1 | AFFINITY LIGAND FOR THE PURIFICATION OF GLYCOSYLATED BIOMOLECULES | HOCHSCHULE FÜR TECHNIK UND WIRTSCHAFT (HTW) BERLIN (DE) | 2017-08-31 | — | — | WO | disclosed |
| US-20170247375-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-08-31 | — | — | US | disclosed |
| US-9718811-B2 | (S)-enantiomer of mepazine | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2017-08-01 | — | — | US | disclosed |
| EP-3191484-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2017-07-19 | — | — | EP | disclosed |
| WO-2017071793-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
| US-9631098-B2 | Dispersing agent comprising fillers or pigments | AMRIL AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016206771-A1 | LIQUID CRYSTAL MEDIUM CONTAINING POLYMERISABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016206774-A1 | LIQUID CRYSTAL MEDIUM CONTAINING POLYMERISABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016206772-A1 | LIQUID CRYSTAL MEDIUM CONTAINING POLYMERISABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016188932-A2 | COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-12-01 | — | — | WO | disclosed |
| EP-3095827-A1 | COMPOSITIONS BASED ON ORGANOSILICON COMPOUNDS AND THEIR USE AS COATING MATERIAL, IN PARTICULAR FOR THE CORROSION PROTECTION OF METALS | MIPA SE (DE) | 2016-11-23 | — | — | EP | disclosed |
| WO-2016162405-A1 | PYRONE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016151066-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA LECB | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2016-09-29 | — | — | WO | disclosed |
| EP-3061779-A1 | Coating agent and the use of same, in particular for forming a protective coating on a surface | Mipa AG (DE) | 2016-08-31 | — | — | EP | disclosed |
| US-20160230069-A1 | ENVIRONMENTAL FRIENDLY WELL TREATMENT FLUIDS COMPRISING AN ESTER | BANK OF AMERICA, N.A., AS THE ADMINISTRATIVE AGENT | 2016-08-11 | — | — | US | disclosed |
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN (DE) | 2016-08-04 | — | — | US | disclosed |
| WO-2016098028-A1 | END CAPPED NUCLEIC ACID MOLECULES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| EP-3024910-A1 | ENVIRONMENTAL FRIENDLY WELL TREATMENT FLUIDS COMPRISING AN ESTER | Amril AG (CH) | 2016-06-01 | — | — | EP | disclosed |
| EP-3021847-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-20160137635-A1 | THE (S)-ENANTIOMER OF MEPAZINE | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-19 | — | — | US | disclosed |
| WO-2016075137-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-19 | — | — | WO | disclosed |
| EP-3013818-A1 | THE (S)-ENANTIOMER OF MEPAZINE | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9308214-B2 | Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations | MITOTECH S.A. (LU) | 2016-04-12 | — | — | US | disclosed |
| US-9295717-B2 | Vaccine composition comprising 5′-cap modified RNA | BIONTECH AG (DE) | 2016-03-29 | — | — | US | disclosed |
| WO-2016038045-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-03-17 | — | — | WO | disclosed |
| EP-2993174-A1 | Pyrazolopyridine derivatives and their use in therapy | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015062656-A9 | ENVIRONMENTAL FRIENDLY WELL TREATMENT FLUIDS COMPRISING AN ESTER | AMRIL AG (CH) | 2016-01-28 | — | — | WO | disclosed |
| US-20150232669-A1 | DISPERSING AGENT COMPRISING FILLERS OR PIGMENTS | AMRIL AG (CH) | 2015-08-20 | — | — | US | disclosed |
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG (DE) | 2015-07-30 | — | — | US | disclosed |
| EP-2895462-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | Baden-Württemberg Stiftung gGmbH (DE) | 2015-07-22 | — | — | EP | disclosed |
| WO-2015062656-A1 | ENVIRONMENTAL FRIENDLY WELL TREATMENT FLUIDS COMPRISING AN ESTER | AMRIL AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| EP-2861675-A1 | DISPERSING AGENT COMPRISING FILLERS OR PIGMENTS | Amril AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| EP-2852572-A1 | CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | Eli Lilly and Company (US) | 2015-04-01 | — | — | EP | disclosed |
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | LILLY CO ELI (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2015007730-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2015-01-22 | — | — | WO | disclosed |
| US-8932557-B2 | Imaging agents for detecting neurological dysfunction | ELI LILLY AND COMPANY (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2014207067-A1 | THE (S)-ENANTIOMER OF MEPAZINE | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2014-12-31 | — | — | WO | disclosed |
| EP-2807214-A1 | STABILIZER COMPOSITIONS FOR THERMOPLASTIC POLYMERS | Amril AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| EP-2461833-B1 | VACCINE COMPOSITION COMPRISING 5'-CAP MODIFIED RNA | BIONTECH AG (DE) | 2014-10-08 | — | — | EP | disclosed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2014124698-A1 | ESTER LUBRICANT FOR OILFIELD- AND OTHER INDUSTRIAL LUBRICANT APPLICATIONS | AMRIL AG (CH) | 2014-08-21 | — | — | WO | disclosed |
| WO-2014086478-A1 | INHIBITORS OF MALT1 PROTEASE | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-8709745-B2 | Methods for isolating ligands of the human bitter taste receptor TAS2R49 | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE (DE) | 2014-04-29 | — | — | US | disclosed |
| WO-2014041125-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | BADEN-WÜRTTEMBERG STIFTUNG GMBH (DE) | 2014-03-20 | — | — | WO | disclosed |
| US-8673578-B2 | Methods of identifying antagonists of the hTAS2R46 bitter taste receptor | Deutsches Institut für Ernahrungsforschung Potsdam-Rehbrücke (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20130345296-A1 | Compositions Comprising a Taxane for Coating Medical Devices | AVIDAL VASCULAR GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| WO-2013185849-A1 | DISPERSING AGENT COMPRISING FILLERS OR PIGMENTS | AMRIL AG (CH) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013176698-A1 | CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | ELI LILLY AND COMPANY (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-2632450-A1 | COMPOSITIONS COMPRISING A TAXANE FOR COATING MEDICAL DEVICES | Avidal Vascular GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| US-8524465-B2 | Agonists of bitter taste receptors and uses thereof | DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG POTSDAM-REHBRUECKE (DE) | 2013-09-03 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-20130203843-A1 | MILD CATIONIC MITOCHONDRIAL UNCOUPLERS | LIMITED LIABILITY COMPANY MITOTECH | 2013-08-08 | — | — | US | disclosed |
| WO-2013110291-A1 | STABILIZER COMPOSITIONS FOR THERMOPLASTIC POLYMERS | AMRIL AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123326-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDTJYLLAND (DK) | 2013-05-16 | — | — | US | disclosed |
| US-8404712-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-26 | — | — | US | disclosed |
| US-20120309703-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG POTSDAM-REHBRUECKE (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8309314-B2 | Agonists of bitter taste receptors and uses thereof | DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG POTSDAM-REHBRUECKE (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20120283324-A1 | ANTAGONISTS AND AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FUR EMAHRUNGSFORSCHUNG POTSDAM-REHBRUCKE (DE) | 2012-11-08 | — | — | US | disclosed |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2012-11-01 | — | — | US | disclosed |
| EP-2494350-A1 | ANTAGONISTS AND AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120208845-A1 | Agonists and Antagonists of Human Bitter Taste Receptor TAS2R49 and Uses Thereof | DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG POTSDAM-REHBRUECKE (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120195917-A1 | Vaccine Composition Comprising 5'-CAP Modified RNA | OCV Intellectual Capital , LLC (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2461833-A1 | VACCINE COMPOSITION COMPRISING 5'-CAP MODIFIED RNA | Biontech AG (DE) | 2012-06-13 | — | — | EP | disclosed |
| EP-2460010-A1 | AGONISTS AND ANTAGONISTS OF HUMAN BITTER TASTE RECEPTOR TAS2R49 AND USES THEREOF | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20120095048-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDT JYLLAND (DK) | 2012-04-19 | — | — | US | disclosed |
| US-8158442-B2 | Antagonists of bitter taste receptors and uses thereof | Deutsches Institut Fuer Ernaehrungsforschung Potsdam-Rehbruecke-Stiftung Des Oefentlichen Rechts (DE) | 2012-04-17 | — | — | US | disclosed |
| WO-2012028311-A1 | COMPOSITIONS COMPRISING A TAXANE FOR COATING MEDICAL DEVICES | AVIDAL VASCULAR GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-8124639-B2 | Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| EP-2398760-A1 | ALLOSTERIC BINDING COMPOUNDS | Aarhus Universitet (DK) | 2011-12-28 | — | — | EP | disclosed |
| US-8043823-B2 | Methods of identifying agonists and antagonists of hTASR bitter taste receptors | DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-8039483-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | disclosed |
| US-20110245207-A1 | METHOD FOR MODERATELY INCREASING THE PROTON CONDUCTIVITY OF BIOLOGICAL MEMBRANES WITH THE AID OF MITOCHONDRIA-TARGETED DELOCALIZED CATIONS | MITOTECH SA (LU) | 2011-10-06 | — | — | US | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-7951958-B2 | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2011050955-A1 | ANTAGONISTS AND AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE (DE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-7928210-B2 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110070577-A1 | Method for Detecting Target Nucleic Acids Using Template Catalyzed Transfer Reactions | HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2011015347-A1 | VACCINE COMPOSITION COMPRISING 5'-CAP MODIFIED RNA | BIONTECH AG (DE) | 2011-02-10 | — | — | WO | disclosed |
| EP-2281579-A1 | Vaccine composition comprising 5'-Cap modified RNA | BioNTech AG (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2011012298-A1 | AGONISTS AND ANTAGONISTS OF HUMAN BITTER TASTE RECEPTOR TAS2R49 AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE (DE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011000566-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEGATIVE-SENSE SSRNA VIRUS INFECTIONS | SAVIRA PHARMACEUTICALS GMBH (AT) | 2011-01-06 | — | — | WO | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
| EP-2247558-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | Siemens Medical Solutions USA, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7795447-B2 | 4-(Acylaminoacetylamino)imidazole derivatives, e.g., methyl 3-(4-{2-[2-(3,5-Difluorophenyl)acetylamino]pentanoylamino}imidazol-1-yl)butyrate; treating neurodegenerative and/or neurological disorders such as Alzheimer's disease and Down's Syndrome | PFIZER INC (US) | 2010-09-14 | — | — | US | disclosed |
| WO-2010094289-A1 | ALLOSTERIC BINDING COMPOUNDS | AARHUS UNIVERSITET (DK) | 2010-08-26 | — | — | WO | disclosed |
| US-7781435-B2 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100184796-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER INC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100168107-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100130498-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSHES INSTITUT FUR ERNAHRUNGSFORSCHUNG POTSDAM- REHBRUCKE (DE) | 2010-05-27 | — | — | US | disclosed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100113548-A1 | ANTAGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FUR ERNAHRUNGSFORSCHUNG POTSDAM-REHBRUCKE (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010017827-A1 | 6-SUBSTITUTED 1-SULFONYL-2, 3-DIHYDRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2010-02-18 | — | — | WO | disclosed |
| US-20100035922-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-11 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| EP-2137530-A2 | ANTAGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| EP-2132564-A2 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts (DE) | 2009-12-16 | — | — | EP | disclosed |
| EP-2132563-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009124756-A1 | USE OF APREPITANT AND DERIVATIVES THEREOF FOR THE TREATMENT OF CANCER | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124755-A1 | COMPOUNDS WITH NOVEL MEDICAL USES AND METHOD OF IDENTIFYING SUCH COMPOUNDS | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2009-10-15 | — | — | WO | disclosed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009102498-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| US-7557117-B2 | 4-oxoimidazolidine-2-spiropiperidine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| WO-2009081246-A2 | BICYCLIC DIAMINES AS NICOTINIC RECEPTOR AGONISTS | PFIZER INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| EP-1734957-A4 | THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7521464-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1658072-A4 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
| EP-2027286-A1 | METHODS FOR DETECTING TARGET NUCLEIC ACIDS USING TEMPLATE CATALYZED TRANSFER REACTIONS | Humboldt-Universität zu Berlin (DE) | 2009-02-25 | — | — | EP | disclosed |
| US-20090016958-A1 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-15 | — | — | US | disclosed |
| US-20080318926-A1 | Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives | PFIZER INC | 2008-12-25 | — | — | US | disclosed |
| US-7468386-B2 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1991215-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | Cenix Bioscience GmbH (DE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008135232-A1 | USE AND COMPOSITIONS OF PURINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CORTESE RICCARDO (IT) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008128730-A2 | ANTAGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2008-10-30 | — | — | WO | disclosed |
| EP-1983342-A1 | Antogonists of bitter taste receptors and uses thereof | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand (DE) | 2008-10-22 | — | — | EP | disclosed |
| US-20080249094-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-10-09 | — | — | US | disclosed |
| WO-2008119526-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119527-A2 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POSTDAM-REHBRÜCKE STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2008-10-09 | — | — | WO | disclosed |
| EP-1975612-A1 | Agonists of bitter taste receptors and uses thereof | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand (DE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1975611-A1 | Agonists of bitter taste receptors and uses thereof | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand (DE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1654260-A4 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20080227781-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-09-18 | — | — | US | disclosed |
| WO-2008109080-A2 | NUCLEOSIDE BASED PROLIFERATION IMAGING MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | HUMPHREY JOHN MICHAEL | 2008-09-11 | — | — | US | disclosed |
| US-20080207712-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-08-28 | — | — | US | disclosed |
| EP-1958939-A2 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | Pfizer Products Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7408068-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1940802-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Pfizer Products Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1730119-B1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7384968-B2 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-06-10 | — | — | US | disclosed |
| WO-2008065500-A2 | HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | PFIZER INC. | 2008-06-05 | — | — | US | disclosed |
| US-7381741-B2 | In which the amino is substituted by arylmethyl- or heteroarylmethyl- group, e.g., 2-Methoxybenzyl)-(2-phenylpyrrolidin-3-yl)-amine and 5-{[2-(3-Chloro-phenyl)-pyrrolidin-3-ylamino]-methyl}-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphalen-2-one; neurokinin 1 (Substance P) inhititors | PFIZER INC (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1420020-B1 | 4-OXOIMIDAZOLIDINE-2-SPIROPIPERIDINE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20080108675-A1 | THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-05-08 | — | — | US | disclosed |
| US-7345038-B2 | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | PFIZER, INC (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345095-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-18 | — | — | US | disclosed |
| US-7342118-B2 | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7309709-B2 | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2007-12-18 | — | — | US | disclosed |
| WO-2007134869-A1 | METHODS FOR DETECTING TARGET NUCLEIC ACIDS USING TEMPLATE CATALYZED TRANSFER REACTIONS | HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) | 2007-11-29 | — | — | WO | disclosed |
| EP-1860197-A1 | Method for detecting target nucleic acids using template catalyzed transfer reactions | Humboldt-Universität zu Berlin (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270430-A1 | Methods of Treating Cognitive Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives | PFZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070265327-A1 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007115805-A2 | AURORA KINASE INHIBITORS | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007113005-A2 | 2-SUBSTITUTED 3-AMINOSULFONYL-THIOPHENE DERIVATIVES AS AURORA KINASE INHIBITORS | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007101710-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213368-A1 | N-ETHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | KLEINMAN EDWARD F | 2007-09-13 | — | — | US | disclosed |
| EP-1832283-A1 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | Cenix Bioscience GmbH (DE) | 2007-09-12 | — | — | EP | disclosed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | disclosed |
| US-7244757-B2 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7241798-B2 | NK1 antagonists | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241786-B2 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7238721-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-03 | — | — | US | disclosed |
| US-7232820-B2 | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-06-19 | — | — | US | disclosed |
| EP-1794114-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070129349-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC | 2007-06-07 | — | — | US | disclosed |
| EP-1791541-A2 | METHODS OF TREATING MOOD DISORDERS USING BENZISOXAZOLE CONTAINING DIAZABICYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1791540-A2 | METHODS OF TREATING COGNITIVE DISORDERS USING PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| US-7220865-B2 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2007039170-A1 | ANTAGONISTS OF TOPOISOMERASE ACTIVITY AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078153-A1 | 4-Oxoimidazolidine-2-spiropiperidine derivatives | MSD K.K. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1653952-A4 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2007034326-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
| US-7192964-B2 | 4-oxoimidazolidine-2-spiropiperidine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| WO-2007026224-A2 | 5-HT1B ANTAGONIST COMPOSITION FOR DEPRESSION, ANXIETY AND COGNITION | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1756056-A1 | AZA-BICYCLO[3.1.0]HEX-1-YL DERIVATIVES ACTIVE AS NK1 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1753718-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1753722-A2 | METABOLITES OF (+)-(2S, 3S)-3-(2-METHOXY-5-TRIFLUOROMETHOXYBENZYLAMINO)-2-PHENYL-PIPERIDINE | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1747195-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2007-01-31 | — | — | EP | disclosed |
| US-7163942-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1735292-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1735294-A1 | THIADIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1734957-A2 | THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1735285-A2 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1735288-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1730119-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1715868-A1 | COMBINATIONS OF AN ATYPICAL ANTIPSYCHOTIC AND AN AMINOMETHYLPYRIDYLOXYMETHYL/BENZISOXAZOLE AZABICYCLIC DERIVATIVES FOR TREATING CNS DISORDERS | Pfizer Products Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-7112599-B2 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-7078529-B2 | N-[1-(bi)cycloaliphatic-1H-imidazol-4-yl]-(bi)cycloaliphatic acetamides; central nervous system disorders; enzyme inhibitors of cyclin-dependent kinase-2 and -5, and glycogen synthase kinase-3 | PFIZER INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20060149066-A1 | Imidazole derivatives | PFIZER INC | 2006-07-06 | — | — | US | disclosed |
| EP-1658072-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1654260-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1653952-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060084689-A1 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006032999-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1638935-A1 | NK1 ANTAGONIST | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1636220-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006027691-A2 | METHODS OF TREATING MOOD DISORDERS USING BENZISOXAZOLE CONTAINING DIAZABICYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027692-A2 | METHODS OF TREATING COGNITIVE DISORDERS USING PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1256578-B1 | Thiazole derivatives and their use as cdk inhibitors | PFIZER PROD INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1608648-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | Pfizer Products Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005121085-A1 | AZA-BICYCLO`3.1.0!HEX-1-YL DERIVATIVES ACTIVE AS NK1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005115976-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050272800-A1 | NK1 antagonists | PFIZER INC | 2005-12-08 | — | — | US | disclosed |
| WO-2005113503-A2 | METABOLITES OF (+)-(2S, 3S)-3-(2-METHOXY-5-TRIFLUOROMETHOXYBENZYLAMINO)-2-PHENYL-PIPERIDINE | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20050261342-A1 | Metabolites of (+)-(2S,3S)-3(2-methoxy-5- trifluoromethoxybenzylamino)-2-phenyl-piperidine | PFIZER INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| WO-2005097114-A2 | THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005095365-A1 | OXAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095367-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095368-A1 | THIADIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095348-A2 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095361-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095334-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222223-A1 | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC. | 2005-10-06 | — | — | US | disclosed |
| US-20050222219-A1 | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20050222149-A1 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20050222239-A1 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20050222227-A1 | Oxazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| WO-2005092864-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050222254-A1 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20050209297-A1 | Pyrazole derivatives | PFIZER INC | 2005-09-22 | — | — | US | disclosed |
| WO-2005082370-A1 | COMBINATIONS OF AN ATYPICAL ANTIPSYCHOTIC AND AN AMINOMETHYLPYRIDYLOXYMETHYL/BENZISOXAZOLE AZABICYCLIC DERIVATIVES FOR TREATING CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050171086-A1 | Compositions for treating CNS disorders | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| EP-1551809-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005020991-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | disclosed |
| WO-2005016267-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2005011601-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050026922-A1 | For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| US-20050004363-A1 | 4-oxoimidazolidine-2-spiropiperidine derivatives | MSD K.K. (JP) | 2005-01-06 | — | — | US | disclosed |
| WO-2004110996-A1 | NK1 ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040242666-A1 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040192746-A1 | Thiazole derivatives | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-20040192750-A1 | Antiproliferative agents; anticancer agents; neurodegenerative agents sexual disorders; antidiabetic agents; urogenital disorders; antidiabetic agents; obesity; muscular disorders; aftertreatment surgery; autoimmune disease | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| WO-2004081007-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | disclosed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
| US-6756385-B2 | FERTILITY; ANTIDIABETIC AGENTS | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1420020-A1 | 4-OXOIMIDAZOLIDINE-2-SPIROPIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-19 | — | — | EP | disclosed |
| WO-2004033434-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-6720427-B2 | USED TO TREAT ABNORMAL CELL GROWTH AND CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2004-04-13 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| EP-1313710-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Pfizer Products Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1305295-A1 | IMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030083352-A1 | Synthesis of imidazole intermediates | PFIZER INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030078252-A1 | Thiazole derivatives | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1256578-A1 | Thiazole derivatives and their use as cdk inhibitors | Pfizer Products Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020119963-A1 | Imidazole derivatives | PFIZER PRODUCTS INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020103185-A1 | Pyrazole derivatives | PFIZER PRODUCTS INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002018346-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002010141-A1 | IMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010141-A1 | IMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-02-07 | — | — | WO | disclosed |